<DOC>
	<DOC>NCT01342679</DOC>
	<brief_summary>The purpose of this study is to evaluate complete molecular response of Dasatinib in patients for Philadelphia chromosome-positive chronic myeloid leukemia</brief_summary>
	<brief_title>A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Chronic Myeloid Leukemia in the Chronic Phase 20 years old over ECOG performance status (PS) score 02 Patients for major molecular response (MMR) with no CMR Adequate organ function (hepatic, renal and lung) Signed written informed consent A case with the double cancer of the activity Women who are pregnant or breastfeeding The case of Pleural effusion clearly Patients with complications or a history of severe or uncontrolled cardiovascular failure following have a Myocardial infarction within 6 months have an Angina within 3 months have a Congestive heart failure within 3 months have a suspected congenital QT syndrome have a QTc interval of more than 450msec at baseline A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy Prior treatment with dasatinib Subjects with T315I, F317L and V299L BCRABL point mutations</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>dasatinib</keyword>
	<keyword>complete molecular response</keyword>
</DOC>